Key result
Blood-based biomarkers show emerging utility across ischemic stroke prediction, diagnosis, and prognosis.
Answers are grounded in this paper and cite their sources.
Ischemic stroke is a leading cause of adult disability and mortality. With over 15 million strokes occurring every year in the world, methods to better identify patients at risk for stroke are needed, as are methods to improve patient diagnosis and prognosis when stroke occurs. Use of blood-based biomarkers is one method that has been evaluated to predict risk of stroke, diagnose stroke and its causes, predict stroke severity and outcome, and guide prevention therapy. Markers that have been identified include a variety of proteins, nucleic acids and lipids that relate to stroke pathophysiology. The role of blood biomarkers in ischemic stroke is still being defined, and further study is needed to develop blood biomarkers for clinical stroke use. In this review, the authors provide a summary of biomarkers that have been divided by their potential clinical application.
No takes yet. Share an insight, caveat, or question.
Rothstein et al. (2013) conducted a review in Ischemic stroke. Blood-based biomarkers (proteins, nucleic acids, lipids) was evaluated. Blood-based biomarkers (proteins, nucleic acids, lipids) have been evaluated for ischemic stroke risk prediction, diagnosis, and prognosis, though their clinical role is still being defined.
Synapse has enriched 5 related papers. Consider them for comparative context: